---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-012774"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:34:08.816338+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary reports net loss of $246K; going concern doubt flagged

## Summary
- BriaPro incurred net loss of $245,960 for six months ended Jan 31, 2024 (no prior-year comparison).
- Assets of $207,432 (mainly intangible patents) offset by $250,678 current liabilities; shareholders' deficit of $231,367.
- Going concern note: 'significant doubt' about ability to continue as pre-clinical stage company needs further financing.
- Due to parent BriaCell $196,549 under transition services agreement; warrant liability of $188,121 recorded.
- Operating loss of $257,057; R&D expenses $168,536 and G&A $88,494 for the six-month period.

## SEC filing metadata
- accession: 0001493152-24-012774
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315224012774/0001493152-24-012774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315224012774/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-012774
- JSON: https://secwatch.observer/filing/0001493152-24-012774.json
- Plain text: https://secwatch.observer/filing/0001493152-24-012774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.